Speculating here. If one trial if one trial in Europe is the outcome - and seems due "in next few weeks" (given hx likely in December) - what do you think the market will do? On one hand, we have appx 60% of addressable market in the EU and a quicker path to commercialisation event.
One the other hand FDA seems to be a key to the market opinion.
My opinion, will be a decent but not over the top re-rate to if one trial in EU. Appx $1.
I think this firms as the likely scenario.
Like to hear your thoughts.
Ann: Notice of Investor Call and Presentation, page-115
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 137000 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.7¢ | 5755 | 1 |
View Market Depth
| Last trade - 16.12pm 18/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable